Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood pressure drug shows promise in slowing Parkinson's progression

NCT ID NCT05109364

Disease control Sponsor: Cedars-Sinai Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether terazosin, a drug usually used for high blood pressure, can slow the progression of Parkinson's disease. Researchers are tracking changes in heart and brain scans of 15 people who are either in early stages or at high risk for Parkinson's. The goal is to see if the drug can protect nerve cells and delay symptoms over three years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Enrolled in the study "The Effect of alpha1- adrenergic receptor antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease" (STUDY #000540) * Capacity to give informed consent Exclusion Criteria: * Secondary Parkinsonism, including tardive * Concurrent dementia defined by a score lower than 22 on The Montreal Cognitive Assessment (MoCA) * Concurrent severe depression defined by a Beck Depression Inventory-Fast Screen (BDI fast screen) score greater than 13 * Comorbidities related to sympathetic nervous system (SNS) hyperactivity * Heart failure (LVEF \<45%) * Recent myocardial revascularization (\<12 weeks) * Hypertension (systolic blood pressure SBP\>150mmHg (millimeters of mercury) or diastolic blood pressure DBP\>100mmHg) * Chronic Atrial fibrillation * Concurrent Use of Beta-adrenergic antagonist * Diabetes mellitus * Chronic Obstructive Pulmonary Disease (COPD) * Untreated Sever Sleep Apnea; Apnea-Hypopnea Index (AHI) \> 30/h. * Severely reduced kidney function (Glomerular Filtration Rate\<30ml/min) * Contraindications to the use of terazosin * Recent myocardial infarction (\<48 h) * Ongoing angina pectoris * Cardiogenic shock or prolonged hypotension * Breast-feeding * Current use of phosphodiesterase type 5 inhibitors: sildenafil (ViagraTM), tadalafil (CialisTM), or vardenafil (LevitraTM) * History of priapism (persistent and painful erection) * Neurogenic orthostatic hypotension defined as symptomatic decrease in BP \> 20mmHg systolic or \> 10mmHg diastolic and HR increase \< 20bpm on supine to sitting or standing. * Blood pressure less than 110 mm Hg systolic at screening or baseline visit * Use of investigational drugs within 30 days before screening * For female participant, pregnancy, or plans for child-bearing during study period * Allergy/hypersensitivity to iodine or study medication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-motor Parkinson's disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Nerve Degeneration Parkinson disease primary dysautonomia REM sleep behavior disorder secondary Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-motor Parkinson's disease Rem sleep behavior disorder Symptomatic Parkinson disease

Contacts and locations

Locations

  • Cedars Sinai Medical Center

    Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.